304 related articles for article (PubMed ID: 20368206)
1. Review article: Thiazolidinediones and heart failure.
Chaggar PS; Shaw SM; Williams SG
Diab Vasc Dis Res; 2009 Jul; 6(3):146-52. PubMed ID: 20368206
[TBL] [Abstract][Full Text] [Related]
2. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
3. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
[TBL] [Abstract][Full Text] [Related]
4. Effects of the thiazolidinedione medications on micro- and macrovascular complications in patients with diabetes--update 2008.
Rohatgi A; McGuire DK
Cardiovasc Drugs Ther; 2008 Jun; 22(3):233-40. PubMed ID: 18373186
[TBL] [Abstract][Full Text] [Related]
5. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
6. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
Patel C; Wyne KL; McGuire DK
Diab Vasc Dis Res; 2005 May; 2(2):61-6. PubMed ID: 16305060
[TBL] [Abstract][Full Text] [Related]
7. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials.
Hernandez AV; Usmani A; Rajamanickam A; Moheet A
Am J Cardiovasc Drugs; 2011; 11(2):115-28. PubMed ID: 21294599
[TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Krentz A
Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
[TBL] [Abstract][Full Text] [Related]
9. Type 2 diabetes, thiazolidinediones, and cardiovascular risk.
Taylor C; Hobbs FD
Br J Gen Pract; 2009 Jul; 59(564):520-4. PubMed ID: 19567003
[TBL] [Abstract][Full Text] [Related]
10. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.
Lago RM; Singh PP; Nesto RW
Lancet; 2007 Sep; 370(9593):1129-36. PubMed ID: 17905165
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone: side effect and safety profile.
Shah P; Mudaliar S
Expert Opin Drug Saf; 2010 Mar; 9(2):347-54. PubMed ID: 20175701
[TBL] [Abstract][Full Text] [Related]
12. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
[TBL] [Abstract][Full Text] [Related]
13. [Heart failure with thiazolidinedione treatment: what do we know today?].
Erdmann E
Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858
[TBL] [Abstract][Full Text] [Related]
14. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
Defronzo RA; Mehta RJ; Schnure JJ
Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
[TBL] [Abstract][Full Text] [Related]
15. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
[TBL] [Abstract][Full Text] [Related]
16. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
17. Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings.
Jain R; Mullins CD; Lee H; Wong W
Res Social Adm Pharm; 2012; 8(1):47-59. PubMed ID: 21733760
[TBL] [Abstract][Full Text] [Related]
18. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis.
Castagno D; Baird-Gunning J; Jhund PS; Biondi-Zoccai G; MacDonald MR; Petrie MC; Gaita F; McMurray JJ
Am Heart J; 2011 Nov; 162(5):938-948.e2. PubMed ID: 22093212
[TBL] [Abstract][Full Text] [Related]
19. The safety of thiazolidinediones.
Tolman KG
Expert Opin Drug Saf; 2011 May; 10(3):419-28. PubMed ID: 21366501
[TBL] [Abstract][Full Text] [Related]
20. Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure.
Granberry MC; Hawkins JB; Franks AM
Am J Health Syst Pharm; 2007 May; 64(9):931-6. PubMed ID: 17468147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
